270 related articles for article (PubMed ID: 29865084)
21. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.
Shirendeb U; Reddy AP; Manczak M; Calkins MJ; Mao P; Tagle DA; Reddy PH
Hum Mol Genet; 2011 Apr; 20(7):1438-55. PubMed ID: 21257639
[TBL] [Abstract][Full Text] [Related]
22. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
[TBL] [Abstract][Full Text] [Related]
23. Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis.
Gipson TA; Neueder A; Wexler NS; Bates GP; Housman D
RNA Biol; 2013 Nov; 10(11):1647-52. PubMed ID: 24256709
[TBL] [Abstract][Full Text] [Related]
24. Small molecule splicing modifiers with systemic HTT-lowering activity.
Bhattacharyya A; Trotta CR; Narasimhan J; Wiedinger KJ; Li W; Effenberger KA; Woll MG; Jani MB; Risher N; Yeh S; Cheng Y; Sydorenko N; Moon YC; Karp GM; Weetall M; Dakka A; Gabbeta V; Naryshkin NA; Graci JD; Tripodi T; Southwell A; Hayden M; Colacino JM; Peltz SW
Nat Commun; 2021 Dec; 12(1):7299. PubMed ID: 34911927
[TBL] [Abstract][Full Text] [Related]
25. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
26. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
27. Widespread dysregulation of mRNA splicing implicates RNA processing in the development and progression of Huntington's disease.
Tano V; Utami KH; Yusof NABM; Bégin J; Tan WWL; Pouladi MA; Langley SR
EBioMedicine; 2023 Aug; 94():104720. PubMed ID: 37481821
[TBL] [Abstract][Full Text] [Related]
28. Analysis of mutant and total huntingtin expression in Huntington's disease murine models.
Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A
Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120
[TBL] [Abstract][Full Text] [Related]
29. Mutant Huntingtin Protein Interaction Map Implicates Dysregulation of Multiple Cellular Pathways in Neurodegeneration of Huntington's Disease.
Podvin S; Rosenthal SB; Poon W; Wei E; Fisch KM; Hook V
J Huntingtons Dis; 2022; 11(3):243-267. PubMed ID: 35871359
[TBL] [Abstract][Full Text] [Related]
30. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.
Chaturvedi RK; Hennessey T; Johri A; Tiwari SK; Mishra D; Agarwal S; Kim YS; Beal MF
Hum Mol Genet; 2012 Aug; 21(15):3474-88. PubMed ID: 22589249
[TBL] [Abstract][Full Text] [Related]
31. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
[TBL] [Abstract][Full Text] [Related]
32. Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C.
Peng C; Zhu G; Liu X; Li H
Neurosci Bull; 2018 Oct; 34(5):747-758. PubMed ID: 29713895
[TBL] [Abstract][Full Text] [Related]
33. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients.
Neueder A; Landles C; Ghosh R; Howland D; Myers RH; Faull RLM; Tabrizi SJ; Bates GP
Sci Rep; 2017 May; 7(1):1307. PubMed ID: 28465506
[TBL] [Abstract][Full Text] [Related]
34. RNA toxicity induced by expanded CAG repeats in Huntington's disease.
Martí E
Brain Pathol; 2016 Nov; 26(6):779-786. PubMed ID: 27529325
[TBL] [Abstract][Full Text] [Related]
35. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
36. Making (anti-) sense out of huntingtin levels in Huntington disease.
Evers MM; Schut MH; Pepers BA; Atalar M; van Belzen MJ; Faull RL; Roos RA; van Roon-Mom WM
Mol Neurodegener; 2015 Apr; 10():21. PubMed ID: 25928884
[TBL] [Abstract][Full Text] [Related]
37. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
[TBL] [Abstract][Full Text] [Related]
38. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.
Bañez-Coronel M; Porta S; Kagerbauer B; Mateu-Huertas E; Pantano L; Ferrer I; Guzmán M; Estivill X; Martí E
PLoS Genet; 2012; 8(2):e1002481. PubMed ID: 22383888
[TBL] [Abstract][Full Text] [Related]
39. Fluorescence Imaging of Huntingtin mRNA Knockdown.
Oh E; Liu Y; Sonar MV; Merry DE; Wickstrom E
Bioconjug Chem; 2018 Apr; 29(4):1276-1282. PubMed ID: 29451775
[TBL] [Abstract][Full Text] [Related]
40. Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models.
Franich NR; Basso M; André EA; Ochaba J; Kumar A; Thein S; Fote G; Kachemov M; Lau AL; Yeung SY; Osmand A; Zeitlin SO; Ratan RR; Thompson LM; Steffan JS
J Huntingtons Dis; 2018; 7(2):137-150. PubMed ID: 29843246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
